Review of NICE Technology Appraisal Guidance no. 100; Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer

TA 100; Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer  is currently on the list of static guidance and therefore does not have a specified review date. 

A review date relates to the time at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake an update of the existing guidance. Because NICE has been asked to develop a clinical guideline for the diagnosis and management of colorectal cancer, and this appraisal is relevant to that work, we have decided to look at this evidence now to inform production of the clinical guideline.

Having re-run the search strategy from the original assessment report the Institute has not found any relevant additions to the evidence base that would have a material effect on the guidance. The newly identified evidence is not likely to change the current guidance. Consequently, we propose that the original guidance should be incorporated into the on-going clinical guideline; Diagnosis and management of colorectal cancer; with mention of the licence extension for capecitabine to include combination therapy.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted.

April 2011